The integrated research organization (IRO) Circuit Clinical will provide patient identification, engagement, enrollment, and other support services as part of its collaboration with the Roswell Park Comprehensive Cancer Center, a National Cancer Institute (NCI) designated cancer center in Upstate New York.
The collaboration marks Circuit Clinical’s entry into oncology clinical research as part of Roswell Park's CIMAvax Clinical Trial for certain forms of lung and head/neck cancer.
Thomas Schwaab, MD, PhD, Roswell Park's chief of strategy, business development and outreach, said in a statement: "We want to make sure that patients throughout our community who are eligible to participate in the CIMAvax Clinical Trial have a convenient opportunity to do so, whether they are getting their care at our main campus or one of our community practices."
In addition to its main campus in Buffalo, NY, Roswell Park will offer the trial at its satellite offices in Amherst and Niagara Falls as well as at its five affiliated community practices.
Also based in Buffalo, NY, Circuit Clinical recently partnered with the University at Buffalo’s (UB) genomics and biorepository program to add personalized medicine capabilities to its service offering lineup.
Circuit Clinical’s TrialScout platform – which rates and reviews clinical research sites – was developed in part with support from the University’s Center for Advanced Technology (UB CAT). UB awarded the company a $200,000 grant in late 2018.
